US Broker Ratings

REGENXBIO Inc. (RGNX) Stock Analysis: Unpacking a Potential 224% Upside in the Biotech Sector

Individual investors eyeing opportunities in the biotechnology sector might find REGENXBIO Inc. (NASDAQ: RGNX) an intriguing proposition. With a robust pipeline and significant potential for stock appreciation, this clinical-stage biotech..

Savara, Inc. (SVRA) Stock Analysis: Unveiling a Promising 217.83% Upside Potential in the Biotech Sector

Savara, Inc. (NASDAQ: SVRA), a burgeoning name in the biotechnology sector, is making waves with its focus on rare respiratory diseases. Currently priced at $2.93, the stock has seen a..

iRadimed Corporation (IRMD) Stock Analysis: A 35.81% Upside Beckons for Healthcare Investors

iRadimed Corporation (IRMD), a prominent player in the healthcare sector specializing in MRI-compatible medical devices, is generating buzz among investors with its promising upside potential. With a market capitalization of..

uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology

As the biotechnology sector continues to capture investor attention, uniQure N.V. (NASDAQ: QURE) emerges as a compelling player with significant growth potential. Based in Amsterdam, Netherlands, uniQure is a frontrunner..

Geron Corporation (GERN): Investor Outlook Highlights a 149% Potential Upside in the Biotech Sector

Geron Corporation (NASDAQ: GERN), a key player in the biotechnology sector, is capturing investor attention with its substantial potential upside of 149.16%. This California-based biopharmaceutical company is at the forefront..

Intellia Therapeutics (NTLA) Stock Analysis: A Potential 325% Upside in Gene Editing Biotech

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering entity in the biotechnology sector, is currently capturing investor interest with its intriguing potential for significant upside. Despite a challenging fiscal landscape, the..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a 172% Upside Potential in the Biotech Sector

Ardelyx, Inc. (NASDAQ: ARDX) stands as an intriguing prospect within the biotechnology sector, primarily driven by its innovative approach to addressing unmet medical needs. With a market capitalization of $947.45..

Avanos Medical, Inc. (AVNS) Stock Analysis: Exploring 12.18% Potential Upside Amid Challenging Market Dynamics

Avanos Medical, Inc. (NYSE: AVNS), a key player in the medical device industry, is currently navigating through a landscape characterized by both opportunities and challenges. With a market capitalization of..

GH Research PLC (GHRS): Biotechnology with a Potential 206% Upside – Investor Insights

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company based in Dublin, Ireland, is capturing the attention of investors with its ambitious approach to treating depression and a remarkable potential..

AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring the 82% Upside Potential in Biotech Innovations

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company based in San Diego, California, is making waves in the healthcare sector with its innovative approach to immunology therapeutics. This relatively small..

CureVac N.V. (CVAC) Stock Analysis: Exploring a 51% Upside in the mRNA Space

CureVac N.V. (CVAC), a pioneering biopharmaceutical company specializing in mRNA technology, has been making waves in the biotechnology sector with its innovative approach to developing transformative medicines. Headquartered in Tübingen,..

Iovance Biotherapeutics, Inc. (IOVA): Exploring a Potential 511% Upside in Biotech Innovation

For investors with a keen interest in the biotechnology sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) represents an intriguing opportunity, particularly given its ambitious potential upside of 511.43%. Anchored in the..

Evolus, Inc. Common Stock (EOLS)

⚠️ No article content returned.

..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating a Potential 7.53% Upside Amid Healthcare Challenges

Community Health Systems, Inc. (NYSE: CYH) stands as a significant player in the healthcare sector, operating a network of general acute care hospitals across the United States. With a market..

InnovAge Holding Corp. (INNV) Stock Analysis: Evaluating a 24.38% Upside Potential in Healthcare

InnovAge Holding Corp. (NASDAQ: INNV), a key player in the healthcare sector, is gaining attention among investors due to its significant upside potential. With a current market capitalization of $542.75..

Dianthus Therapeutics, Inc. (DNTH) Investor Outlook: Exploring a 179.96% Potential Upside in Biotechnology

For investors eyeing the healthcare sector, Dianthus Therapeutics, Inc. (NASDAQ: DNTH) offers an intriguing opportunity, particularly in the dynamic biotechnology industry. Headquartered in New York, this clinical-stage company focuses on..

Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring a Potential 248% Upside in the Biotech Sector

Nuvation Bio Inc. (NUVB) is capturing the attention of investors with a remarkable potential upside of 248.15%, according to analyst ratings. Operating within the dynamic biotechnology industry, Nuvation Bio is..

Beta Bionics, Inc. (BBNX) Stock Analysis: Potential 61% Upside in the Healthcare Sector

Beta Bionics, Inc. (BBNX), a promising player in the healthcare sector, is steadily capturing investor interest with its innovative solutions in the medical devices industry. Specializing in enhancing the quality..

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Promising 43.45% Potential Upside in the Healthcare Sector

Delcath Systems, Inc. (NASDAQ: DCTH) stands out in the medical devices industry with its innovative approach to treating liver cancers. Known for its HEPZATO KIT, this New York-headquartered company specializes..

Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Unpacking the 78.41% Potential Upside

In the ever-evolving landscape of the biotechnology sector, Gyre Therapeutics, Inc. (NASDAQ: GYRE) has positioned itself as a notable player, developing innovative therapies to combat debilitating fibrotic and inflammatory diseases...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds